A Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults in Good General Heath
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
A Phase 1 Randomized, Double-blinded, Placebo-controlled, Dose-escalation Clinical Trial to
Evaluate the Safety and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults in Good General
Health
Phase:
Phase 1
Details
Lead Sponsor:
International AIDS Vaccine Initiative
Collaborators:
Brigham and Women's Hospital East-West Medical Research Institute George Washington University Redemption Hospital